1. Home
  2. CYPH vs MLCI Comparison

CYPH vs MLCI Comparison

Compare CYPH & MLCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$0.99

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

MLCI

Mount Logan Capital Inc.

N/A

Current Price

$4.35

Market Cap

69.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CYPH
MLCI
Founded
2011
N/A
Country
United States
United States
Employees
6
21
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
73.4M
69.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYPH
MLCI
Price
$0.99
$4.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5M
22.9K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
2.63%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$3.31
52 Week High
$3.70
$8.68

Technical Indicators

Market Signals
Indicator
CYPH
MLCI
Relative Strength Index (RSI) 60.96 49.95
Support Level $0.94 $3.31
Resistance Level $1.01 $7.98
Average True Range (ATR) 0.10 0.25
MACD 0.00 0.07
Stochastic Oscillator 66.66 42.31

Price Performance

Historical Comparison
CYPH
MLCI

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About MLCI Mount Logan Capital Inc.

Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.

Share on Social Networks: